Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

IGC Pharma reports strategic growth and progress in Alzheimer's research in Q2 2025

IGC Pharma reported revenue of $310,000 and a projected loss per share of -$0.02 in the second quarter of 2025, with a focus on strategic development in Alzheimer's research and operational efficiency. The company expanded its clinical trial sites and plans to launch a new diagnostic platform, but remains unprofitable for now due to its long-term research focus. CEO Ram Cunda emphasized the company's innovation and its goal to address Alzheimer's with new therapeutic approaches. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, IGC RESOURCES INC. has already paid €1.93 in dividends. The last payout was in July 2023.

Financials

In the last quarter, IGC RESOURCES INC. had revenue of €21.96m and net profit of €2.58m

(EUR)	June 2026	YoY
Revenue	21.96m	18.03%
Gross profit	7.97m	4.47%
Net profit	2.58m	151.21%
EBITDA	2.12m	14.22%

Fundamentals

Metric	Value
Market capitalization	€43.64m
Number of shares	38.47m
52-week high/low	€1.44 - €0.82
Dividends	No
Beta	0.45
P/E ratio	-112.50
PEG ratio	0.81
P/B ratio	1.07
P/S ratio	0.54

Company profile

Decibel Cannabis Company Inc. engages in the cultivation, processing, production, and retail sale of cannabis products in Canada. It offers cannabis flower, cannabis pre-rolls, and cannabis biomass to licensed producers in Canada. The company is also involved in the extraction, processing, and manufacturing of various cannabis derivative products, including vape cartridges, cannabis infused products, and cannabis extracts. It offers its products under the Qwest, Qwest Reserve, Blendcraft by Qwest, and General Admission brands. Decibel Cannabis Company Inc. is headquartered in Calgary, Canada.